Literature DB >> 8120109

Determination of the enantiomers of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in plasma and urine using enantioselective gas chromatography with mass spectrometric detection.

C P Granville1, B Gehrcke, W A König, I W Wainer.   

Abstract

A rapid, sensitive, enantioselective gas chromatographic method has been developed for the quantitation of the enantiomers of ifosfamide (IFF) and its 2- and 3-dechloroethylated metabolites (2-DCE-IFF and 3-DCE-IFF) in human and animal plasma and human urine. IFF and the two dechloroethylated metabolites were extracted into chloroform, enantioselectively resolved by gas chromatography on a chiral stationary phase based upon heptakis(2,6-di-O-methyl- 3-O-pentyl)-beta-cyclodextrin and quantitated using mass-selective detection with selected-ion monitoring. The limits of quantitation for the enantiomers of IFF, 2-DCE-IFF and 3-DCE-IFF in plasma were 250 and 500 ng/ml respectively. In urine, the limits of quantitation for the enantiomers of IFF, 2-DCE-IFF and 3-DCE-IFF were 500 ng/ml. The method can detect concentrations as low as 250 ng/ml of each enantiomer of 2- and 3-DCE-IFF in plasma and urine. The intra- and inter-day coefficients of variation for this method were with one exception less than 8%. The assay was validated for enantioselective pharmacokinetic studies in humans and rats and is the first reported enantioselective assay for the measurement of the enantiomers of 2- and 3-DCE-IFF in plasma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8120109     DOI: 10.1016/0378-4347(93)80245-y

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Stereoselective pharmacokinetics of ifosfamide in male and female rats.

Authors:  J J Wang; H Lu; K K Chan
Journal:  AAPS PharmSci       Date:  2000

3.  New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.

Authors:  M P Di Marco; I W Wainer; C L Granvil; G Batist; M P Ducharme
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

4.  Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.

Authors:  Regina V Oliveira; Joelle M Onorato; Danuta Siluk; Christine M Walko; Celeste Lindley; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2007-08-02       Impact factor: 3.935

5.  Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Authors:  C P Granvil; J Ducharme; B Leyland-Jones; M Trudeau; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.